tomaralimab   Click here for help

GtoPdb Ligand ID: 9408

Synonyms: OPN-305 | OPN305 | VK5A/H4
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tomaralimab (OPN305) is a first-in-class humanised monoclonal antibody against Toll-like receptor 2 (TLR2) being developed by Opsona Therapeutics. It is being investigated for potential clinical use in certain hematological and immunological conditions. OPN305 and its possible uses are claimed in patent WO2011003925 [4]. The effect of TLR2 antagonism on myocardial ischemia/reperfusion injury in a large animal model (pigs) is reported in [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
OPN305 is a first-in-class humanised anti-TLR2 mAb that is being investigated for potential clinical use in certain hematological and immunological conditions.